Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514486 · ClinicalTrials.gov registry record
Assessment of Cancer Concerns at the End of Treatment (ACE)
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 332
- Enrollment target
NCT02514486 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 332 participants.
The verdict
NCT02514486 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 332 participants
- Enrollment target
Study Summary
This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate provider satisfaction following delivery of an electronic health record (HER)/EPIC summary of these PROs. Secondary aims will estimate differences in referral to available services between those providers exposed to the PRO summary and historical controls. BC survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (EOT)/survivorship focused visit will be the focus of this study.
Interventions
- BEHAVIORAL Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-01-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02514486
The ClinicalTrials.gov registry entry for NCT02514486 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Questionnaire is the first listed.
NCT02514486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02514486 about?
NCT02514486 is a clinical study titled "Assessment of Cancer Concerns at the End of Treatment (ACE)". This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect ...
What is the current status of trial NCT02514486?
This trial is currently completed. The enrollment target is 332 participants. The study started on 2014-07. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT02514486?
The interventions under investigation include: Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT02514486?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.